Reach Healthcare will debut a three-part exhibition at HLTH 2022 entitled "Beyond the Ordinary." It will showcase three multi-sensory immersive solutions for transforming health and well-being care and take attendees on a three-part experiential journey that explores new modalities for addressing: workforce wellness and clinician burnout; improving maternal-infant health outcomes; and boosting post-operative and transitional recovery, rehabilitation and chronic healthcare management.

Reach Healthcare experiences will be centrally located in the Bassano Rooms (#2602, 2603 and 2604) during HLTH 2022, which runs Nov 13 through 16 at the Venetian Expo and Convention Center in Las Vegas NV.

"What if we focused more on sensory elements in health centers, birth centers, diagnostic centers, nursing homes, rehabilitation centers…even hospital-at-home and retail health?" Reach's President, Fran Ayalasomayajula, asks. The Reach sensory solutions go beyond tossing a plant in a corner or drowning out spaces with white noise. 

"For centuries research has shown the power of sensory stimulation to heal, revive, and restore," Reach's President, Fran Ayalasomayajula, points out. At HLTH, Reach will present a walking gallery experience infused with elements that stimulate the senses, through the application of transformational and immersive sound and music, visual effects and imagery, textures, smells and tactile interaction. 

This first-time offering at HLTH will showcase ways technology can be used to harness positive, calming, healing, and restorative experiences. It will serve as a departure from traditional approaches.

"HLTH is pleased to have Reach Healthcare host their breakthrough immersive therapeutic approach to health and wellbeing at this year's event. This is an important area of focus for HLTH and aligns perfectly with our recently launched brand - WELL by HLTH," said Rich Scarfo, President of HLTH.

Reach Healthcare's mission is to provide a platform that delivers groundbreaking solutions to improve and transform healthcare delivery and outcomes for providers and patients, as well as to offer cost-effective solutions for payers. 

THE SCIENCE OF HEALING and WELLNESS:  BENEFITS OF MULTISENSORY EXPERIENCES

Reach Healthcare's "Beyond the Ordinary" experiences at HLTH are built on three relevant scientific findings: 

• Healthcare Settings Matter. In a 2020 Clinical Empathy study that Reach commissioned with Ipsos, a key finding was that environments matter. Patients seek supportive and familiar environments, and they also place a high value on milestones and memories associated with their environments. 

Healthcare Settings directly affect the patient's overall health and well-being, since they also impact relationships, including those of care teams and healthcare consumers. Reach Healthcare solutions enable care facilities, especially hospitals and healthcare providers, to deliver a less stressful experience and minimize the upset and friction between the patient with their providers.

• Sounds and Music Matter. Additional research by Reach revealed that listening to certain sounds and music can reduce anxiety and pain, blood pressure and heart rate, improve sleep quality, mood, mental alertness and memory -- and shorten the length of hospital stays. The layering of digital multimedia and cinematography also delivers similar positive health outcomes. 
• Sounds are not limited to the patient journey - but also extend to the provider. The Aesthetic Surgery Journal reported that researchers from the University of Texas Medical Branch at Galveston found that plastic surgeons closed incisions better and faster when done -- while listening to their preferred music.

OTHER COLLABORATIONS

"Beyond the Ordinary" presented by REACH comes to life with the engagement of Reach's technology partners, including HARMAN Digital Transformation Solutions (DTS). REACH's Happy Mama, a maternity app and decision support tool for maternal health professionals, is powered by the HARMAN Remote Care Platform (RCP). Happy Mama will be on display as part of the activation

HARMAN International is a wholly-owned subsidiary of Samsung Electronics Co., Ltd. that is focused on connected technologies for automotive, consumer and enterprise markets. 

This collaboration with visual effects powered by Samsung Digital Display Division joins others within the Reach orbit. They include: Birth & Life Photography and MovingArt by Louis Schwartzberg, as seen on Oprah (OWN), Netflix, and Reach Live. 

Other contributors to the "Beyond the Ordinary" presented by Reach include OddBall, HealthTunes, Spatial Inc., and Visual Health Solutions. 

Reach Healthcare's "Beyond the Ordinary Experience" at HLTH 2022 "takes the attendee on a holistic therapeutic journey through the art and science of healing and wellness -- with the help of immersive multisensory technologies that deliver solutions from a 'people-first' perspective to transform everyday lives," concludes Reach's President, Fran Ayalasomayajula.

ABOUT HLTH 2022:

HLTH (pronounced "health") is the leading platform bringing together the entire health ecosystem, focused on health innovation and transformation. From unparalleled events with industry-leading speakers to inspirational digital content and mission-driven initiatives, HLTH creates a unique marketplace for the health community leading the dialogue and development of a better health ecosystem. Our mission is to gather the health community in curated, purposeful engagements that accelerate healthcare innovation.

Event Registration:  https://www.hlth.com/2022event

Media - Special Exhibition Tours: https://www.hlth.com/2022event/media

#hlth2022

ABOUT REACH

REACH is a 501c3 global innovative social impact organization whose mission is to improve and transform healthcare delivery and outcomes for providers and patients, as well as to offer cost-effective solutions for payers. 

Maternal mortality and morbidity prevention is a top priority area for the organization. Reach is the founder of the National Save Moms Campaign (http://savemoms.us), Save Moms Global (http://savemoms.global), Maternal Application of Technology for Community Health (MATCH) Coalition (http://matchcoalition.us), and Happy Mama (http://happymama.global).

Reach, established in 2016,  is focused on pragmatically improving large-scale and sustainable health programs for enhanced healthcare equity, access, and delivery based on its four pillars: (1) Research to identify where change is needed that could result in actionable outcomes; (2) Education; (3) Thought Leadership and (4) Innovative Immersive Special Interest Therapeutic Platforms, including Happy Mama, focused on maternal health for mothers as well as clinicians; Workforce Wellness to tackle clinician burnout; and IB Healthy Wellness and Remote Care digital therapeutics for rehab, chronic disease management, healthy aging, and more.

Reach welcomes new partnerships, sponsorships, and grassroots affiliates as it works to drive massive impact for better and more equitable healthcare outcomes.

Despite centuries of research, treating and curing cancer remains an urgent health research priority. With generous support from anonymous donors, the GastroIntestinal Research Foundation (GIRF) has launched a bold initiative, CA CURE, to identify and fund research to improve diagnostics and develop therapeutics focused on immunotherapies and personalized vaccines. CA CURE will focus on projects that might have difficulty attracting funds because they are too experimental or are in the initial stages of development. As always, the Foundation's focus is improving patient outcomes, and it will fund rigorously evaluated science from across the country. 

Chaired by Sonia Kupfer, MD, Associate Professor of Medicine, Co-Director of the Comprehensive Cancer Risk and Prevention Clinic, and Director of the Gastrointestinal Cancer Risk and Prevention Clinic at UChicago Medicine, CA CURE's research review process is advised by a team of multi-disciplinary medical experts from across the country  

The Foundation's President, Yekaterina Chudnovsky, said, "CA CURE is a bold and innovative approach to identify, treat and even one day cure digestive cancers. Far too many people, at younger and younger ages are diagnosed with fatal cancers, often after living with a digestive disease such as Crohn's, ulcerative colitis, fatty liver disease, and others. Despite its prevalence, colon cancer research is grossly underfunded. CA CURE will quickly put vital research dollars in the hands of leading scientists."   

Since its recent inception, the Foundation has funded three projects.  

Elicio Therapeutics will use its GIRF funding on research for two therapeutic cancer vaccines. Both vaccines have been designed with Elicio's proprietary lymph node-targeting Amphiphile (AMP) platform that "educates" T cells on how to target particular antigens, such as mutated proteins in cancer. ELI-007 is being developed to target the BRAF gene mutation, and ELI-008 is being developed to target hotspot mutations in p53 in solid tumors including colorectal cancer. These AMP vaccines will educate T cells on how to recognize the BRAF and p53 mutations for a potentially better immune response against the tumor. BRAF V600E mutations are present in 10% of colon cancer while mutations in p53 are found in approximately 60% of patients with solid tumors. 

Rarecyte has been funded to test gastrointestinal cancer patient samples within clinical trials to determine circulating tumor cell (CTC) burden and selected biomarker analysis. CTCs have long been understood to be shed from the tumor into the bloodstream with the potential to embed at distant and discrete sites within the body generating metastatic dissemination of the tumor. Metastatic disease resulting from this process is the leading cause of cancer-related deaths. CTCs have been shown to be a strong indicator of prognosis in cancer patients. The emerging trend of personalized medicine ('patient-specific therapy') requires deeper understanding of the makeup of CTCs, both at the protein and gene level, to select therapies which will specifically treat the individual patient's cancer. 

Funding to Dr. Christopher Mason at Weill Cornell Medicine (WCM) will support research utilizing a cutting-edge, sub-cellular spatial profiling technology to reveal novel aspects of colorectal cancer (CRC) heterogeneity and improve our understanding of normal tissues, at both the RNA and protein levels. To date, spatial imaging technologies (e.g., GeoMx) have shown a wealth of novel tissue complexity and biology. Yet their ability to guide research has been hampered because the technology has yet to be fully harnessed. Using a multi-disciplinary approach, Dr. Mason's study will address this issue by developing a powerful resource that will catapult the future impact of spatial technologies and demonstrate the utility of these technologies to evaluate Spatially-resolved Atlas CRC tumors, both metastatic and primary, and normal colon tissues. The results will provide an unprecedented resource for the study of CRC and normal biology, allowing investigators using GeoMx and CosMx technology to experience the full potential of these platforms in their research. Dr. Mason's research will help develop data analysis pipelines and machine learning techniques that can advance the analysis of NanoString data. These efforts will also provide invaluable resources for future studies, allowing for the search for novel therapeutic targets to cure cancer. 

------------------------------------------------------------------------------------------------------------------ 

About the GastroIntestinal Research Foundation 

In 1961, GIRF was founded by grateful patients and friends of the late Dr. Joseph B. Kirsner, a pioneer in gastroenterology, who devoted his life to medicine, teaching, and patient care. Since then, in partnership with University of Chicago Medicine Digestive Diseases Center, GIRF has given millions to support research to improve treatment of, seek cures for and prevent digestive diseases.  

NICaS By NI Medical
Company Logo

NI Medical, the inventors of NICaS, the non-invasive hemodynamic monitoring tool, has joined the American Heart Association Center for Health Technology & Innovation's (the Center) Innovators' Network. The Center is focused on building and fostering health technology relationships to develop innovative and scalable solutions.

The Innovators' Network is a healthcare-focused technology consortium that connects entrepreneurs, providers, researchers and payers. Innovators' Network members also have access to the Association's digital guidelines, recommendations, and best-in-class science as they develop digital healthcare technologies. Members collaborate with the Center in different ways, including the building of models for clinical outcome studies, lowering the significant cost of developing those studies independently, helping connect the science to technology, and providing evidence that a digital platform improves healthcare outcomes - a key concern for providers and payers.

"The Center aims to advance the rapid, efficient, and effective development of healthcare technology," said Robert A. Harrington, M.D., FAHA, past president of the American Heart Association (2019-2020), volunteer chair of the American Heart Association's Health Tech Advisory Group for the Center and Arthur L. Bloomfield professor and chair department of medicine, Stanford University. "Joining the Innovators' Network gives members the opportunity to leverage the consortium and work toward broadening and deepening their engagement in this arena."

"Excited to become a part of this exceptional network and join forces to deliver our unique solution for heart failure and hypertension patients management," says Eyal Karev, CEO of NI Medical.

About NI Medical

NI Medical joins the Innovators' Network, bringing with them NICaS, a non-invasive, cost-effective and highly validated hemodynamic management solution. 

NICaS is the only whole-body bioimpedance tool that has extensive clinical validation and accuracy capabilities equal to the gold standard (Thermodilution) with extremely high reproducibility. The solution's greatness lies in its ability to provide the cause for the patient's hemodynamic instability - and not only the symptom.

NI Medical presents significant expertise in bioimpedance technology globally. Having developed NICaS, the only whole-body noninvasive hemodynamic management solution, the company has been active globally and in the U.S. market for several years. The solution allows for improved personalized patient therapy, mainly in heart failure and hypertension disease management, as well as other chronic conditions. The solution is highly validated from technology, clinical and commercial perspectives. 

MEDIA CONTACT:

Jenny Chernikh
[email protected]